Mr. Schor is Co-Founder, President and Chief Executive Officer of resTORbio. Mr. Schor has led biotech companies across all stages, from formation and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Prior to co-founding resTORbio, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL). Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to commercial success.
Mr. Schor led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds an M.B.A., a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).